(1)海洋药用微生物资源的挖掘
(2)海洋来源新颖结构天然产物的分离鉴定和活性筛选
(3)海洋药物先导化合物的机制研究和成药性评价

2003-09--2008-06  华中科技大学同济医学院   研究生  博士
1999-09--2003-06  华中科技大学同济医学院   本科生  学士

2018-12至今  中国科学院南海海洋研究所 研究员
2010-12--2018-12  中国科学院南海海洋研究所 副研究员
2014-06--2015-06  美国加州大学圣地亚哥分校Scripps海洋研究所(Fenical's Lab)访问学者
2008-07--2010-12  中国科学院南海海洋研究所 助理研究员

1. 海洋放线菌来源粉蝶霉素衍生物的定向构建和以PRDX1为靶点的抗肾癌先导物优化，主持，NSFC面上项目，2020-2023。
2. 北部湾海洋微生物资源多样性评估、药用开发与利用的前期研究，合作单位负责人，NSFC区域创新联合重点项目，2021-2024。
3. 南海海洋微生物药物先导物资源发现及活性评价，子课题负责人，海南省重大科技计划项目，2020-2023。
4. 基于ADME/T成药特性的抗肾癌海洋候选药GPAs靶向制剂研发，合作单位负责人，广东省海洋经济发展专项，2021-2023。
5. 海洋药物研究开发创新团队， 核心成员，“广东特支计划”本土创新创业团队项目，2020-2025.

1. 近3年来代表性论文（通讯作者）：
(1)  Ping Yu#, Tanwei Gu#, et al., Yingfeng Tu*, Lan Tang*, Xuefeng Zhou*. A novel marine-derived anti-acute kidney injury agent targeting peroxiredoxin 1 and its nanodelivery strategy based on ADME optimization. Acta Pharmaceutica Sinica B, 2024. doi:10.1016/j.apsb.2024.03.005. (IF14.5)
(2) Chunmei Chen#, Lingxiang Xiao#, Xiaowei Luo#, et al., Xuefeng Zhou,* Yanhui Tan,* and Yonghong Liu*. Identifying marine-derived tanzawaic acid derivatives as novel inhibitors against osteoclastogenesis and osteoporosis via downregulation of NF-κB and NFATc1 activation. Journal of Medicinal Chemistry, 2024, 67, 4, 2602–2618
(3) Jian Cai#, Li Gao#, Yue Wang#, et al., Yanhui Tan*, Meng Jin*, Xuefeng Zhou*. Discovery of a novel anti-osteoporotic agent from marine fungus-derived structurally diverse sirenins. European Journal of Medicinal Chemistry, 2024, 265, 116068.
(4) Yuwei Fang#, Jianglian She#, et al., Lan Tang*, Xuefeng Zhou*. Discovery of Anti-Hypercholesterolemia Agents Targeting LXRα from Marine Microorganism-Derived Natural Products. Journal of Natural Products 2024. 2024, 87, 2, 322-331
(5) 陈仪, 佘江链, 唐斓, 刘永宏, 周雪峰*. 海洋特征天然产物——硝基苯酯倍半萜类的研究进展[J]. 药学学报, 2024, 59(1): 35-42.
(6) Jiaqi Liang, Jianglian She, Jun Fu, Jiamin Wang, Yuxiu Ye, Bin Yang, Yonghong Liu, Xuefeng Zhou*, Huaming Tao*. Advances in Natural Products from the Marine-Sponge-Associated Microorganisms with Antimicrobial Activity in the Last Decade. Marine Drugs 2023, 21, 236.
(7) Jian Cai#, Xueni Wang#, Xia Gan, Qian Zhou, Xiaowei Luo, Bin Yang, Yonghong Liu, Disna Ratnasekera*, and Xuefeng Zhou*. New Chlorinated Metabolites and Antiproliferative Polyketone from the Mangrove Sediments-Derived Fungus Mollisia sp. SCSIO41409. Marine Drugs 2023; 21(1):32.
(8) Yuxiu Ye, Jiaqi Liang, Jianglian She, Xiuping Lin, Junfeng Wang, Yonghong Liu, Dehua Yang, Yanhui Tan*, Xiaowei Luo*, and Xuefeng Zhou*. Two New Alkaloids and a New Butenolide Derivative from the Beibu Gulf Sponge-Derived Fungus Penicillium sp. SCSIO 41413. Marine Drugs. 2023; 21(1):27. (IF 6.085)
(9)  Bo Peng#, Jian Cai#, Zimin Xiao, Manli Liu, Xinlong Li, Bin Yang, Wei Fang, Yi-You Huang, Chunmei Chen*, Xuefeng Zhou*, Huaming Tao*. Bioactive Polyketides and Benzene Derivatives from Two Mangrove Sediment-Derived Fungi in the Beibu Gulf. Marine Drugs 2023, 21: 327.
(10) Tanwei Gu, Weihao Chen, Jianglian She, Bin Yang, Lan Tang, Huaming Tao, Jingxia Huang*, and Xuefeng Zhou*. Lipid metabolism regulatory activity and adverse effects of fungi-derived butyrolactone I. Natural Product Research, 2023, 37(11):1897-1901.
(11) Canzhen Liu#, Xiaoxu Wang#, Xiaonan Wang#, Yunfang Zhang#, Wenjian Min, Ping Yu, Jinhua Miao, Weiwei Shen, Shuangqin Chen, Shan Zhou, Xiaolong Li, Ping Meng, Qinyu Wu, Fan Fan Hou, Youhua Liu, Peng Yang, Cheng Wang*, Xu Lin*, Lan Tang*, Xuefeng Zhou*, Lili Zhou*. A new LKB1 activator, piericidin analogue S14, retards renal fibrosis through promoting autophagy and mitochondrial homeostasis in renal tubular epithelial cells. Theranostics. 2022; 12(16): 7158-7179. (IF 11.6)
(12) Jianglian She, Yi Chen, Yuxiu Ye, Xiuping Lin, Bin Yang, Jiao Xiao, Yonghong Liu, and Xuefeng Zhou*. New Carboxamides and a New Polyketide from the Sponge-Derived Fungus Arthrinium sp. SCSIO 41421. Marine Drugs. 2022, 20, 475. (IF 6.085)
(13) Bo Peng, Qingyun Peng*, Jianglian She, Bin Yang, Xuefeng Zhou*. Secondary Metabolites from the Coral-Derived Fungus Aspergillus terreus SCSIO41404 with Pancreatic Lipase Inhibitory Activities. Records of Natural Products. 2022, 16(6), 639 - 644
(14) Kunlong Li, Siqiang Chen, Xiaoyan Pang, Jian Cai, Xinya Zhang, Yonghong Liu, Yiguang Zhu*, Xuefeng Zhou*. Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis. European Journal of Medicinal Chemistry. 2022, 230, 114117. (Cover Article, IF 7.088)
(15) Qingyun Peng#,Weihao Chen#, Xiuping Lin, Jiao Xiao, Yonghong Liu, Xuefeng Zhou*. Butenolides from the Coral-Derived Fungus Aspergillius terreus SCSIO41404. Marine Drugs. 2022, 20, 212. (IF 6.085)
(16) Ziqi Su, Kunlong Li, Xiaowei Luo, Yongyan Zhu, Shao-Yu Mai, Quanhong Zhu, Bin Yang, Xuefeng Zhou*, Huaming Tao*. Aromatic Acids and Leucine Derivatives Produced from the Deep-Sea Actinomycetes Streptomyces chumphonensis SCSIO15079 with Antihyperlipidemic Activities. Marine Drugs. 2022, 20, 259. (IF 6.085)
(17) Jian Cai, Xueni Wang, Zaizhun Yang, Yanhui Tan*, Bo Peng*, Yonghong Liu, Xuefeng Zhou*. Thiodiketopiperazines and Alkane Derivatives Produced by the Mangrove Sediment-Derived Fungus Penicillium ludwigii SCSIO 41408. Frontiers in Microbiology 2022, 13, 857041. (IF 6.064)
(18) Jianglian She, Tanwei Gu, Xiaoyan Pang, Yonghong Liu, Lan Tang*, Xuefeng Zhou*. Natural Products Targeting Liver X Receptors or Farnesoid X Receptor. Frontiers in Pharmacology. 2022, 12, 772435 (IF 5.81)
(19) Yanhui Tan, Minhong Ke, Zhichao Li, Yan Chen, Jiehuang Zheng, Yiyuan Wang, Xuefeng Zhou*, Gang Huang* and Xiaojuan Li*. A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation via Suppressing c-Fos-NFATc1 Signaling Pathway. Frontiers in Pharmacology. 2022, 12, 753240 (IF 5.81)
(20) Kunlong Li#, Yu Dai#, Jianglian She, Yanbo Zeng, Hao-fu Dai, Shunlin Ou*, Xuefeng Zhou*, Yonghong Liu*. Bisabolanoic acid A, a new polychiral sesquiterpene with AChE inhibitory activity from a mangrove-derived fungus Colletotrichum sp. Journal of Asian Natural Products Research 2022, 24, 88-95
(21) 叶禹秀, 罗小卫, 杨斌, 林秀萍, 刘永宏, 周雪峰*.南海礁栖海藻共附生真菌Pestalotiopsis neglecta SCSIO41403次级代谢产物研究[J]. 热带海洋学报, 2022,  41(3): 186-190.
2. 授权专利情况：
(1)周雪峰,唐斓,李坤龙,杨斌,陶华明,刘永宏. 一种吡啶酮粉蝶霉素及其制备方法和在制备抗癌药物中的应用. ZL 202110687275.7, 申请日2021.06.21, 授权日2022-08-05
(2)周雪峰,戴昱,杨斌,林秀萍,刘永宏. 一种苯酞甘油醚类化合物及其制备方法和在抗海洋生物污损方面的应用.  ZL 202011023962.0, 申请日2020-09-25；授权日2022-07-12.
(3)周雪峰,唐斓,王健娇,杨斌,林秀萍,刘永宏. 一种香叶基三羟基色酮及其制备方法和在制备肝X受体激动剂中的应用.  ZL202010442043.0, 申请日2020.05.22, 授权日2022-04-26
(4)周雪峰,李坤龙,唐斓,杨斌,刘永宏. 两个支链异构化粉蝶霉素类化合物及其在抗肾癌药物中的应用. 202010442011.0, 申请日2020.05.22, 授权日2021.08.24
(5)周雪峰,唐斓,王健娇,李坤龙,杨斌,刘永宏.一种炔烯对苯二酚糖苷及其在制备肝X受体激动剂中的应用. ZL202010258928.5, 授权日2021.06.11.
(6)周雪峰,唐斓,方伟,罗小卫,李坤龙,刘永宏. 两个粉蝶霉素葡萄糖苷及其在抗肾癌药物中的应用. ZL201811340841.1, 授权日2020.11.06.
(7)周雪峰,唐斓,方伟,李坤龙,刘永宏. 三个粉蝶霉素类天然产物及其在制备抗肾癌药物中的应用. ZL201811340842.6, 授权日2020.10.20.
(8)周雪峰,杨斌,林秀萍,唐斓,李晓娟,刘永宏. 一类硝基苯酯倍半萜类化合物及其在制备抗肾癌药物中的应用. ZL201710861987.X, 授权日2020.08.11.
(9)周雪峰,唐斓,李坤龙,方伟,刘永宏. 一种链霉菌及其代谢产物粉蝶霉素类化合物在抗肾癌中的应用. ZL201710344174.3, 授权日2020.05.12.
(10)周雪峰,方伟,林秀萍,刘永宏.倍半萜硝基苯酯类化合物及其制备方法和在制备抗肿瘤药物中的应用. ZL 201310464296.8, 授权日2015.03.11
(11)周雪峰; 刘永宏; 徐暾海; 杨献文; 黄日明; 王隶书. 一种来源于海绵的甾醇及其提取方法和应用. ZL200910193049.2, 授权日2012.09.26

1.广东省自然科学杰出青年基金获得者
2.广东省特支计划“百千万工程青年拔尖人才”
3.广州市“珠江科技新星”

1.中国药学会海洋药物专业委员会委员
2.中国药学会海洋药物专业委员会“海洋药物博士论坛”青年委员会委员
3.广东省海洋协会海洋生物分会秘书长
4.​国际期刊Marine Drugs编委（Editorial Board Member）
5.《Chinese Chemistry Letters》青年编委